Therapeutic Focus

Neurolixis Inc. is focused on pre-clinical drug discovery and early clinical development of candidates targeting unmet needs in the field of neurological and neuropsychiatric illness. Priority clinical programs target Parkinson's disease and Rett syndrome.
In addition, Neurolixis pursues drug discovery projects targeting mood disorders and cognitive deficits, which are a debilitating feature of CNS diseases and often exhibit treatment resistance to currently-available treatments.

Parkinson's disease

Parkinson's disease (PD) is one of the most common nervous system disorders of the elderly. The movement-related symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise whereas depression is the most common psychiatric symptom. Prolonged treatment with the antiparkinsonian drug, L-DOPA, elicits dyskinesia as a side-effect. Neurolixis is developing NLX-112 to alleviate this. More...

Rett syndrome

Rett syndrome (RTT) is a severely debilitating, genetically-encoded orphan disorder that occurs almost exclusively in females and is characterized by arrested development between 6 and 18 months of age, regression of acquired skills, loss of speech, seizures, and mental retardation. Among the symptoms of RTT, dysrhythmic breathing, cognitive deficits and movement difficulties are particularly disturbing and Neurolixis is developing NLX-101 to treat RTT. More...